Sage Therapeutics' (SAGE) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE - Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $12.00 price target on the biopharmaceutical company's stock.

A number of other equities analysts have also weighed in on the company. Bank of America began coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price objective for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a report on Monday. Wall Street Zen cut Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 7th. Finally, Canaccord Genuity Group upped their price objective on Sage Therapeutics from $8.00 to $8.50 and gave the stock a "hold" rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $8.93.

Sage Therapeutics Price Performance

SAGE traded up $0.17 during trading on Tuesday, reaching $9.30. 2,600,424 shares of the company's stock were exchanged, compared to its average volume of 1,284,783. Sage Therapeutics has a 1 year low of $4.62 and a 1 year high of $13.47. The company's fifty day simple moving average is $7.20 and its 200-day simple moving average is $6.98. The stock has a market capitalization of $582.37 million, a P/E ratio of -1.60 and a beta of 0.18.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). The business had revenue of $14.06 million for the quarter, compared to analysts' expectations of $14.12 million. Sage Therapeutics had a negative return on equity of 68.99% and a negative net margin of 747.63%. The company's revenue for the quarter was up 78.0% on a year-over-year basis. During the same period last year, the business earned ($1.80) EPS. Equities analysts forecast that Sage Therapeutics will post -3.52 EPS for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. AlphaQuest LLC acquired a new position in Sage Therapeutics during the first quarter worth $32,000. Picton Mahoney Asset Management grew its position in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 3,581 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Sage Therapeutics during the first quarter worth about $37,000. KLP Kapitalforvaltning AS acquired a new position in shares of Sage Therapeutics during the 4th quarter worth about $49,000. Finally, Ieq Capital LLC acquired a new position in shares of Sage Therapeutics during the 4th quarter worth about $57,000. Institutional investors and hedge funds own 99.22% of the company's stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.